Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the publication of new preclinical research in the peer-reviewed Journal of Virology, demonstrating significant differences in virulence between the mpox virus clade IIb, currently circulating in the U.S., and the historic clade IIa strain. The study, conducted at the company’s research and development center, identified three new mouse models for investigating mpox pathogenesis and found that the clade IIb isolate is up to 100,000 times less virulent than clade IIa. This provides additional tools to evaluate vaccines and other medical countermeasures.
The findings support continued development of TNX-801, Tonix’s live attenuated horsepox virus vaccine candidate for the prevention of mpox and smallpox. The company believes the new animal models will help researchers better understand emerging mpox variants, assess vaccine durability and protective efficacy, and advance efforts to address the ongoing global threat posed by the disease. For more details, view the full press release at https://ibn.fm/ZlMkM.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s CNS portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years, as well as acute migraine products Zembrace SymTouch and Tosymra. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
This research is crucial as it provides a deeper understanding of mpox virulence and offers new models for testing vaccines, which is vital for public health preparedness. The development of TNX-801 could potentially offer a safer and more effective vaccine against mpox and smallpox, addressing a significant unmet need. The findings also highlight the importance of ongoing research to stay ahead of evolving viral threats.
For the latest news and updates relating to TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.
